Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Item

http://www.wikidata.org/entity/Q38744286

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Adding Celecoxib With or Witho ...... , Randomized Controlled Trial.

@en

type

Item

label

Adding Celecoxib With or Witho ...... , Randomized Controlled Trial.

@en

prefLabel

Adding Celecoxib With or Witho ...... , Randomized Controlled Trial.

@en

P1476

Adding Celecoxib With or Witho ...... m, Randomized Controlled Trial

@en

P2093

Alastair W S Ritchie

http://www.w3.org/2001/XMLSchema#string

Andrew Protheroe

http://www.w3.org/2001/XMLSchema#string

Anna Lydon

http://www.w3.org/2001/XMLSchema#string

Ashok D Nikapota

http://www.w3.org/2001/XMLSchema#string

Azman Ibrahim

http://www.w3.org/2001/XMLSchema#string

Catherine Walmsley

http://www.w3.org/2001/XMLSchema#string

Christopher C Parker

http://www.w3.org/2001/XMLSchema#string

Clare Gilson

http://www.w3.org/2001/XMLSchema#string

Cyrill A Rentsch

http://www.w3.org/2001/XMLSchema#string

David Matheson

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer.

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.

P304

1530-1541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.69.0677

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthew R Sydes

John Wagstaff

P577

2017-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28300506

http://www.w3.org/2001/XMLSchema#string

P932

5455701

http://www.w3.org/2001/XMLSchema#string